NCT00006234已完成1 期
A Phase I/II Study of 166Ho-DOTMP With Peripheral Blood Progenitor Cell Support for Refractory or Recurrent Ewing's Sarcoma Family of Tumors With Bone Disease
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 试验地点
- 2
研究概览
简要总结
RATIONALE: Radioactive drugs, such as holmium Ho 166 DOTMP, may carry radiation directly to cancer cells and not harm normal cells. Peripheral stem cell transplantation may be able to replace stem cells that were destroyed by the radioactive drug.
PURPOSE: This Phase I/II trial is studying the effectiveness of holmium Ho 166 DOTMP followed by peripheral stem cell transplantation in treating patients who have metastatic Ewing's sarcoma or rhabdomyosarcoma that has spread to the bone.
详细描述
OBJECTIVES:
- Determine the dosimetry of holmium Ho 166 DOTMP in patients with metastatic Ewing's sarcoma family of tumors or rhabdomyosarcoma with bone metastases.
- Provide treatment with holmium Ho 166 DOTMP for these patients.
- Determine the toxicity and pharmacokinetics of this drug in these patients.
- Determine the change in tumor cell content in peripheral blood and bone marrow after treatment with this drug in these patients.
OUTLINE: Patients receive a trace dose of holmium Ho 166 DOTMP IV over 10 minutes on day -7 and an assigned dose over 10 minutes on day 0. Autologous peripheral blood stem cells are infused on days 7-10.
Patients are followed at least weekly for 4 weeks and then monthly for 1 year or until disease progression.
PROJECTED ACCRUAL: A total of 4 patients will be accrued for this study.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
入排标准
- 年龄范围
- 12 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •DISEASE CHARACTERISTICS:
- •Histologically confirmed Ewing's sarcoma family of tumors or rhabdomyosarcoma with bone metastases
- •Refractory to conventional therapy OR
- •Responsive to conventional therapy with osseous metastases at diagnosis that are extensive enough to preclude concurrent radiotherapy to all sites
- •Soft tissue, pulmonary, and/or bone marrow metastases in addition to cortical bone allowed
- •Extraosseous sites of disease allowed if amenable to surgical resection or external beam radiotherapy
- •No patients under 10 years old with embryonal rhabdomyosarcoma
- •Adequate peripheral blood stem cells stored
- •At least 2,500,000 CD34+ cells/kg
- •No impending bone fracture or spinal cord compression
- •PATIENT CHARACTERISTICS:
- •12 and over
- •Performance status:
- •Life expectancy:
- •At least 2 months
- •Hematopoietic:
- •Absolute neutrophil count at least 1,000/mm^3
- •Platelet count at least 75,000/mm^3 (transfusion independent)
- •Hemoglobin at least 10.0 g/dL (RBC transfusion allowed)
- •Bilirubin no greater than 1.5 times normal
- •SGOT no greater than 2.5 times normal
- •Radioisotope glomerular filtration rate, iothalamate clearance, or creatinine clearance at least 60 mL/min
- •No uncontrolled infection
- •Not pregnant or nursing
- •Negative pregnancy test
- •Fertile patients must use effective contraception
- •PRIOR CONCURRENT THERAPY:
- •Biologic therapy:
- •Recovered from prior immunotherapy
- •At least 3 months since prior bone marrow or peripheral blood stem cell transplantation (6 months for total body irradiation conditioning) and recovered
- •At least 1 week since prior cytokines
- •No immunomodulators during and for at least 4 weeks after study
- •No concurrent cytokines
- •Chemotherapy:
- •At least 3 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovered
- •No more than 3 prior systemic chemotherapy regimens
- •No systemic chemotherapy during and for at least 4 weeks after study
- •Endocrine therapy:
- •Not specified
- •Radiotherapy:
- •See Disease Characteristics
- •See Biologic therapy
- •Recovered from prior radiotherapy
- •No prior maximum tolerable radiotherapy (greater than 30 Gy) to the spinal cord
- •No prior therapeutic doses of bone-seeking radiopharmaceutical (e.g., samarium Sa 153 lexidronam pentasodium EDTMP)
- •No radiotherapy during and for at least 4 weeks after study
- •Local radiotherapy to any tumor site allowed provided at least 1 evaluable lesion is untreated
- •See Disease Characteristics
- •No surgical resection of all bone metastases evaluable by PET during and for 1 month after study
- •At least 4 weeks since prior bisphosphonates
排除标准
- 未提供
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
Radiation Therapy Using Holmium Ho 166 DOTMP Plus Melphalan and Peripheral Stem Cell Transplantation in Treating Patients With Multiple MyelomaMultiple Myeloma and Plasma Cell NeoplasmNCT00004158Fred Hutchinson Cancer Center
已完成
1 期
Samarium Sm 153 Lexidronam Pentasodium and Bortezomib in Treating Patients With Relapsed or Refractory Multiple MyelomaMultiple Myeloma and Plasma Cell NeoplasmNCT00478075Mayo Clinic50
Unknown
1 期
Phosphorus 32 in Treating Patients With Glioblastoma MultiformeBrain and Central Nervous System TumorsNCT00004129Center for Molecular Medicine12
终止
不适用
Individualized Dosimetry for Holmium-166 Radioembolization in Patients With Unresectable Hepatocellular CarcinomaCarcinoma, HepatocellularNCT06302400Imperial College London4
已完成
2 期
Radiation Therapy, Temozolomide, and Irinotecan in Treating Patients With Newly Diagnosed Glioblastoma MultiformeBrain and Central Nervous System TumorsNCT00099125Radiation Therapy Oncology Group170